Complications  of pregnancy-induced hypertension – therapeutic management and prognosis

Krâstev, Boris Marinov; Brăila, Mihai; Pucă, Cristina Maria; Brăila, Anca Daniela

doi:10.26416/gine.30.4.2020.3943

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason may be that nifedipine combined with magnesium sulfate and labetalol can downregulate the expression of endothelin and improve endothelial dysfunction. Nifedipine combined with magnesium sulfate and labetalol can regulate peroxide injury and reduce the release of free radicals to prevent vascular endothelial damage [ 40 , 41 ]. There are some limitations in this study.…”

Section: Discussionmentioning

confidence: 99%

Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension

Yu-ping

Zhang

2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. The purpose is to investigate the influence of nifedipine, labetalol, and magnesium sulfate on blood pressure control, blood coagulation, and maternal and infant outcome in those suffering from pregnancy-induced hypertension (PIH). Methods. From January 2019 to April 2021, 100 participants with PIH in our center were randomly assigned to a control group and a research group. As a control, nifedipine combined with magnesium sulfate was administered. Nifedipine, labetalol, and magnesium sulfate were administered to the research group. The curative effect, blood pressure level, blood coagulation function, vascular endothelial function, and pregnancy comparisons were made between the two groups. Results. Based on the results of the study, the effective rate totaled 92.00%, while as for the control group, it was 80.0%, which indicates that there was a statistically significant difference between the effective rates of the research group and that of the control group, and the difference was statistically significant ( P < 0.05 ). Blood pressure and blood coagulation function did not differ significantly between the two groups before treatment, and the difference was not statistically significant ( P > 0.05 ). After treatment, both groups experienced a significant drop in systolic and diastolic blood pressure. After treatment, a higher PT index was found in the research group than in the control group. Likewise, the Fbg, D-D, and PLT were lower compared to those in the control group, and the difference was statistically significant ( P < 0.05 ). Neither group had significantly different vascular endothelial function before treatment, and the difference was not statistically significant ( P > 0.05 ). After treatment, the ET-1 of the two groups decreased, and the level of NO increased. There was a lower ET-1 in the research group than in the control group as well as a higher NO level in the research group than in the control group, and the difference was statistically significant ( P < 0.05 ). Compared with the pregnancy outcome, in comparison to the controls, the research group had a higher vaginal delivery rate. Significantly, fewer cases of fetal distress, intrauterine asphyxia, and placental abruption were reported in the research group than in the control group, and the difference was statistically significant ( P < 0.05 ). Conclusion. Nifedipine, in combination with magnesium sulfate and labetalol, is effective at treating PIH, reducing blood pressure, improving blood coagulation, preventing cardiovascular events and vascular endothelial function, and further improve the pregnancy outcome.

show abstract

Section: Discussionmentioning

confidence: 99%